ZEJULA (niraparib) patient at yoga class

Why ZEJULA (niraparib)?

ZEJULA is a once-daily, oral maintenance treatment for women with newly diagnosed advanced or recurrent ovarian cancer, after the cancer has completely or partially responded to the most recent chemotherapy.

Take ZEJULA at home, or wherever you are.

 

That leaves more of your day to focus on what matters to you.

 

You don’t have to plan your schedule around ZEJULA. While it should be taken at approximately the same time each day, you can choose a time that’s convenient for you. ZEJULA can be taken with or without food, which means that you’re not tied to meal schedules. If you miss a dose, take the next one at your regularly scheduled time.

Do not take an extra dose to make up for a missed dose. If you vomit after taking a dose of ZEJULA, do not take an extra dose. Take your next dose at your scheduled time.

Treatment with ZEJULA requires routine monitoring. Your healthcare provider will do blood tests to check your blood cell counts before treatment with ZEJULA, weekly for the first month of treatment with ZEJULA, monthly for the next 11 months, then as needed during treatment with ZEJULA.

Your healthcare provider will check your blood pressure and heart rate at least weekly for the first two months, then monthly for the first year, and as needed thereafter during your treatment with ZEJULA.

Get more details on ZEJULA dosing plus information on how your doctor will monitor treatment.

FIND OUT MORE

Women smiling after yoga

AT HOME, OR WHEREVER YOU ARE.

AS A MAINTENANCE THERAPY

 

ZEJULA may offer more time without your cancer recurring,*

 

regardless of certain genetic characteristics, like BRCA status

ZEJULA is used as a maintenance treatment for women with and without a positive test for BRCA or HRD.†‡

 

LEARN MORE ABOUT THE TRIAL DESIGNS

*In a first-line maintenance clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. In a recurrent maintenance clinical trial, ZEJULA delayed disease progression in patients with an inherited BRCA mutation for a median of 21 months vs 6 months with placebo. In patients without an inherited BRCA mutation, ZEJULA delayed disease progression for a median of 9 months vs 4 months with placebo. Results may vary. Median is the middle number in a set of data, also called the midpoint. The trials are ongoing to see if patients live longer overall with treatment.

HRD, or homologous recombination deficiency, occurs when cells have difficulty repairing themselves and appears in about 50% of women with ovarian cancer.
BRCA refers to a set of genes called BRCA1 and BRCA2. Mutations in BRCA genes increase a woman’s risk of developing ovarian cancer, but having a BRCA mutation does not mean a woman will develop ovarian cancer. BRCA mutations can be inherited, or passed from parents to their children.

AS A LATE-LINE TREATMENT

ZEJULA is a treatment option for certain women with advanced ovarian cancer.

 

 

ZEJULA is approved for women with certain genetic characteristics who are experiencing a recurrence and have had at least 3 prior chemotherapy regimens.

LEARN MORE ABOUT THE TRIAL DESIGN

Women enjoying coffee after yoga

ZEJULA is a PARP inhibitor

 

ZEJULA is a medication called a PARP inhibitor. A PARP inhibitor can target cells—including cancer cells—and prevent them from repairing damage to their DNA, which may keep cancer from coming back. ZEJULA can also impact other cells and tissues in the body.


Learn more about how ZEJULA works.

 

LEARN MORE

Is ZEJULA Right for Me?

ZEJULA is an ovarian cancer treatment option that may be used for women at multiple opportunities in their journey—and could be a next step in your path forward.

 

ZEJULA can be used as a:

First-Line Maintenance Treatment

 

For recently diagnosed advanced ovarian cancer that has responded (complete or partial response) to platinum-based chemotherapy

Recurrent Maintenance Treatment

 

For recurrent ovarian cancer that has responded (complete or partial response) to platinum-based chemotherapy

Late-Line Treatment

 

For HRD+§ advanced ovarian cancer after 3 or more prior chemotherapy regimens

§HRD+ advanced ovarian cancer is defined as tumors with a certain BRCA gene mutation, or gene mutation problems and who have progressed more than 6 months after their last treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that ZEJULA is right for you.

Frequently Asked
Questions

What is ZEJULA?

 

SEE ANSWER

Who should consider ZEJULA?

 

SEE ANSWER

How does ZEJULA work?

 

SEE ANSWER